<i>GSTM1</i> and <i>GSTT1</i> polymorphisms in healthy volunteers – a worldwide systematic review

Nakanishi, Giovana; Bertagnolli, Laísa S; Pita-Oliveira, Murilo; Scudeler, Mariana M; Torres-Loureiro, Sabrina; Almeida-Dantas, Thaís; Alves, Maria Laura C; Cirino, Heithor S; Rodrigues‐Soares, Fernanda

doi:10.1080/03602532.2022.2036996

Cited by 9 publications

(5 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To end this discussion, we report a meta‐analysis (Nakanishi et al., 2022) where the PubMed database was searched, including 533 articles and 178,566 people in the analyses. Significant frequency differences existed among different ethnic groups: East Asians have the highest frequencies worldwide for GSTM1 and GSTT1 deletions, which might suggest a higher risk of disorders for this population; in contrast, sub‐Saharan Africans had the lowest frequency worldwide, corroborating previous inferences of evolution for other genes encoding metabolic enzymes.…”

Section: Discussionmentioning

confidence: 99%

“…The GSTT1 gene is genotype‐specific and is absent in 38%–50% of Asian populations (Liang et al., 2013; Nakanishi et al., 2022). Alternative splicing of this gene results in multiple transcript variants (Liang et al., 2013).…”

Section: Introductionmentioning

confidence: 99%

“…Alternative splicing of this gene results in multiple transcript variants (Liang et al., 2013). This gene is located on human chromosome 22q11.2, comprises five exons and is 8 kb long (Kerb et al., 2002; Nakanishi et al., 2022). Several diseases have been associated with gene expression and/or polymorphism of the GSTT1 enzyme, and they include pathologies such as sensitivity to mutagens, Type 2 diabetes mellitus, senile cataract, different carcinomas or de novo autoimmune hepatitis, among others (Al‐Riyami et al., 2022; Ansari‐Lari et al., 2020; Liu et al., 2022; Nassereddine et al., 2021; Nelson et al., 1995; Sobha & Ebenezar, 2021; Stepanova et al., 2021).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Analysis of null deletion polymorphism of glutathione S‐transferase theta (GSTT‐1), associated with anti‐GSTT‐1 antibodies development in transplantation

Muro‐Perez,

González‐Martínez,

Martínez‐García

et al. 2023

Int J Immunogenetics

View full text Add to dashboard Cite

Glutathione S‐transferase theta 1 (GSTT1) is an enzyme involved in phase II biotransformation processes and a member of a multigene family of detoxifying and clearing reactive oxygen species. GSTT1 is polymorphic like other biotransforming enzymes, allowing variability in hepatic conjugation processes. Immunological recognition of the GSTT1 alloantigen, as evidenced by donor‐specific antibodies formation, has previously been observed in recipients lacking GSTT1 protein (called GSTT1−, GSTT*0, null phenotype or homozygous for the GSTT1 deletion) who receive liver or kidney transplants from GSTT1+ donors and is a risk factor for the development of de novo hepatitis following liver transplants from a GSTT1 expressing donor. Antibodies against GSTT1 are demonstrated in patients who are GSTT1 null and received a transplant from a GSTT1+ donor. Understanding the local population frequency of the GSTT1 deletion is of value in understanding the potential clinical risk of developing post‐transplant complications, which can be attributed to the nonexpression of GSTT1. A population of 173 healthy donors of the Murcia Region in Southeast Spain was evaluated for a null allele of GSTT1 (n = 173). DNA was extracted, and GSTT‐1 null allele detection was performed by real‐time polymerase chain reaction. The frequency of the null GSTT1 genotype (nonexpression or deletion of the homozygous polymorphism of the GSTT1 protein) was 17.9% (n = 31 null allele GSTT1/173 total individuals). Our data suggest that the frequency of null GSTT1 mutations in our population in Southeast Spain is 17.9%, lower than in other Caucasoid populations. This would convert our recipient population into more susceptible to nonlocal potential organ donors and less susceptible to local donors. All recipients bearing this GSTT1 deletion homozygous would be without the protein and triggering an alloantigen in the case of transplantation with a donor without deletion.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of null deletion polymorphism of glutathione S‐transferase theta (GSTT‐1), associated with anti‐GSTT‐1 antibodies development in transplantation

Muro‐Perez,

González‐Martínez,

Martínez‐García

et al. 2023

Int J Immunogenetics

View full text Add to dashboard Cite

show abstract

“…These enzymes are implicated in the second-phase metabolism of several compounds, such as anticancer and xenobiotic substances [ 37 ]. Polymorphisms in the GSTT1 gene show significant frequency differences among distinct ethnic groups: East Asians present the highest frequencies worldwide for GSTT1 deletions [ 38 ], which could implicate in higher interindividual variability in pharmacotherapy responses and susceptibility to various diseases, especially those of hepatological disorders [ 39 ]. The results regarding the role of GSTT1 conflict depending on the type of treatment evaluated.…”

Section: Discussionmentioning

confidence: 99%

Pharmacogenomic Profile of Amazonian Amerindians

Rodrigues

Fernandes

Ribeiro-dos-Santos

et al. 2022

JPM

View full text Add to dashboard Cite

Given the role of pharmacogenomics in the large variability observed in drug efficacy/safety, an assessment about the pharmacogenomic profile of patients prior to drug prescription or dose adjustment is paramount to improve adherence to treatment and prevent adverse drug reaction events. A population commonly underrepresented in pharmacogenomic studies is the Native American populations, which have a unique genetic profile due to a long process of geographic isolation and other genetic and evolutionary processes. Here, we describe the pharmacogenetic variability of Native American populations regarding 160 pharmacogenes involved in absorption, distribution, metabolism, and excretion processes and biological pathways of different therapies. Data were obtained through complete exome sequencing of individuals from 12 different Amerindian groups of the Brazilian Amazon. The study reports a total of 3311 variants; of this, 167 are exclusive to Amerindian populations, and 1183 are located in coding regions. Among these new variants, we found non-synonymous coding variants in the DPYD and the IFNL4 genes and variants with high allelic frequencies in intronic regions of the MTHFR, TYMS, GSTT1, and CYP2D6 genes. Additionally, 332 variants with either high or moderate (disruptive or non-disruptive impact in protein effectiveness, respectively) significance were found with a minimum of 1% frequency in the Amazonian Amerindian population. The data reported here serve as scientific basis for future design of specific treatment protocols for Amazonian Amerindian populations as well as for populations admixed with them, such as the Northern Brazilian population.

show abstract

“…Результати продемонстрували, що поліморфізм CYP2D6 і CYP1A2 може бути пов'язаним з чоловічим безпліддям. На додачу, поліморфізм CYP1A2 може збільшити ризик безпліддя у курців, а нульовий генотип GSTM1 пов'язаний з азооспермією [21].…”

Section: малunclassified

Синергія Впливу Поліморфних Варіантів Генів Системи Першої Та Другої Фази Детоксикації Ксенобіотиків І Психо-Емоційного Стресу На Репродуктивне Здоров’я Чоловіка: Огляд Літератури Та Клінічний Випадок

Маковецька¹,

Турова²,

Савельєва³

2023

UJMH

View full text Add to dashboard Cite

В роботі проаналізовано сучасні дані щодо ролі генів детоксикації ксенобіотиків та дії хронічного стресу в патогенезі порушень чоловічої репродуктивної функції. Виявлені генетичні предиктори свідчать про різноманітність індивідуальних патогенетичних механізмів розвитку порушень чоловічої репродуктивної функції, що потребує застосування персоналізованого лікування.

show abstract

GSTM1 and GSTT1 polymorphisms in healthy volunteers – a worldwide systematic review

Cited by 9 publications

References 48 publications

Analysis of null deletion polymorphism of glutathione S‐transferase theta (GSTT‐1), associated with anti‐GSTT‐1 antibodies development in transplantation

Analysis of null deletion polymorphism of glutathione S‐transferase theta (GSTT‐1), associated with anti‐GSTT‐1 antibodies development in transplantation

Pharmacogenomic Profile of Amazonian Amerindians

Contact Info

Product

Resources

About